Lower DME severity seen with ranibizumab treatment

11/13/2012 | Healio

Data from the RIDE and RISE trials showed ranibizumab-treated patients with diabetic macular edema showed lower levels of disease severity that were maintained between 24 and 36 months compared with no change in severity levels for those who received sham treatment. "These data derived from two large randomized trials of ranibizumab for diabetic macular edema provide strong evidence that ranibizumab is effective in reducing diabetic retinopathy severity level," Dr. Michael S. Ip reported at the Retina Subspecialty Day.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR